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To determine the proportion of Escherichia coli O157 
cases in Scotland attributable to secondary spread, we 
analyzed data obtained through entire-population enhanced 
surveillance. We identiﬁ   ed 11% of cases as secondary. 
Secondary cases in single households were younger than 
secondary cases in outbreaks affecting >1 household and 
had similar risk for hemolytic uremic syndrome. 
E
scherichia coli O157 remains a substantial public 
health challenge worldwide, particularly because of its 
association with hemolytic uremic syndrome (HUS) (1,2). 
The low infectious dose (3) exacerbates its potential to 
cause secondary spread and large outbreaks (4–10). Most 
published information about secondary spread derives 
from outbreaks (7,9–12) or from subgroups or settings 
not necessarily generalizable to whole populations (4,11). 
Rates of secondary cases range from 4% to 16% (4,9).
Associations with increased transmission include 
presence of siblings, young age of persons with primary 
or potential secondary cases (4,10,11), and waterborne 
compared with foodborne transmission in outbreaks (12). 
Scotland consistently reports higher rates of E. coli O157 
infection than many other countries (Figure 1); E. coli O157 
was identiﬁ  ed in 81% of HUS cases (13). Although large 
outbreaks have occurred (7,8), most infections in Scotland 
are apparently sporadic (14) (Figure 2).
The Study
In 1999, Health Protection Scotland (HPS), in close 
collaboration with the Scottish E. coli O157/VTEC 
Reference Laboratory (Edinburgh, Scotland), established 
enhanced surveillance of E. coli O157 covering the entire 
population. HPS deﬁ  nes a case as a single-person infection 
episode with laboratory conﬁ  rmation of infection as either 
culture positive or serum positive for E. coli O157. The 
term case refers to symptomatic and asymptomatic persons, 
i.e., patients and nonpatients. 
HPS compiles standardized datasets for all cases, 
integrating microbiologic, epidemiologic, demographic, 
and exposure data; datasets include direct clinical reports 
of HUS under enhanced surveillance of thrombotic 
microangiopathies since 2003 (13) and detailed symptom 
descriptions since 2004. Secondary cases are deﬁ  ned as 
those symptomatic cases from whose onset date and an 
assumed incubation period (<14 days) we can infer that 
contact with a conﬁ  rmed case was more likely than any 
other exposure to be the source of infection, and whose 
onset was >2 days after onset in the contact case. Cases 
having onset within 2 days after onset in a contact case are 
deﬁ  ned as co-primaries. 
HPS surveillance systems collect information about 
general outbreaks, i.e., those affecting members of >1 
household or residents of an institution. Other cases are 
therefore either sporadic or occur among members of a 
single household. For ease of comprehension, we refer to 
cases in general outbreaks as outbreak cases and cases or 
clusters restricted to a single household as sporadic cases, 
irrespective of whether they are secondary or primary 
cases. We analyzed data for all cases reported to HPS 
during 1999–2008 using χ2 and Mann-Whitney tests and 
considered p<0.05 as signiﬁ  cant. 
From January 1, 1999, through December 31, 2008, 
a total of 2,228 E. coli O157 cases were reported to HPS 
(mean 223 annually); the mean annual incidence rate 
was 4.4 cases per 100,000 population (Table 1; Figure 
1). Ages of the 2,228 cases ranged from 4 months to 97 
years (median 21 years). A minority of all cases (202/2,228 
[9%]) were asymptomatic, in similar proportions annually 
(p = 0.44) (Table 1). All 1,118 cases reported 2004–2008 
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Figure 1. Rates per 100,000 population of laboratory-conﬁ  rmed 
culture-positive Escherichia coli O157 cases, by country, United 
Kingdom, 1984–2008. Data outside Scotland courtesy of Health 
Protection Agency London, and Public Health Agency Belfast; 
ﬁ   gures for England, Wales, and Northern Ireland are verotoxin-
positive cases only. Data for 2008 outside Scotland are provisional.E. coli O157 and Secondary Spread, Scotland
provided symptom details; 660 (59%) had bloody diarrhea. 
Varying proportions of cases each year were hospitalized 
(mean 41%; p<0.005) or had illness progressing to HUS 
(196/2,228; mean 9%; p = 0.03) (Table 1). HUS occurred 
more often in cases reporting bloody diarrhea than 
nonbloody diarrhea (14% vs. 3%, p<0.0005), suggesting 
that bloody diarrhea may be a better predictor of progression 
to HUS than was previously apparent in Scotland.
Secondary cases constituted 246/2,026 (12%) of the 
symptomatic cases (11% of all cases), with proportions 
varying annually (range 4%–20%; p<0.0005) (Table 1; 
Figure 2), apparently independent of incidence rates. 
Secondary cases were younger than primary cases (median 
13 years vs. 20 years; p<0.0005). Fewer secondary than 
primary cases had bloody diarrhea (54% vs. 66%; p = 0.02) 
(Table 2), but secondary cases with bloody diarrhea were 
younger than primary cases with bloody diarrhea (median 
13 years vs. 26 years; p<0.03), perhaps reﬂ  ecting lower 
thresholds for screening younger contacts. Secondary cases 
accounted for 12% of all HUS cases, and their likelihood 
of having HUS was similar to that of primary cases (p = 
0.95) (Table 2). Mean time between onset in primary and 
secondary cases was 8 days (range 3–24 days); the longer 
times occurred when primary cases were symptomatic for 
>14 days. Child-to-child transmission accounted for 72% 
of secondary cases, child-to-adult for 19%, and adult-to-
adult for 9%.
Most cases (1,787/2,228 [80%]) were sporadic (Table 
1; Figure 2). Similar proportions of sporadic and outbreak 
cases (p = 0.89) had illness progressing to HUS. Of the 
1,650 sporadic cases who were symptomatic, 158 (10%) 
were secondary cases (Table 2). Sporadic and outbreak 
secondary cases had the same risk for HUS (p = 0.97), but 
sporadic secondary cases were younger (median 9 years 
vs. 26 years; p<0.04), highlighting the need to prevent 
transmission within single households.
Outbreak cases constituted 441/2,228 (20%) cases, 
but proportions varied annually (range 13%–27%; 
p<0.0005) (Table 1; Figure 2). Of the 88 secondary cases 
in outbreaks, 57 (65%) lived in the same household as 
the associated primary case; the remainder were contacts 
either in institutions or in linked second households. The 
441 outbreak cases comprised 104 separate outbreaks. 
Secondary cases were identiﬁ  ed in 40 (42%) of the 95 
outbreaks that occurred in Scotland, with an average ratio 
of secondary to primary cases of 1.3:1.
Conclusions
The reasons for high incidence rates of E. coli O157 
in Scotland are undoubtedly complex and multifactorial. 
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Figure 2. Secondary symptomatic or primary symptomatic 
laboratory-conﬁ  rmed  Escherichia coli O157 cases, by outbreak 
or sporadic occurence, Scotland, 1984–2008. *Only 2 cases were 
identiﬁ  ed in this year.
Table 1. Selected characteristics and health outcomes of laboratory-confirmed Escherichia coli O157 cases, Scotland, 1999–2008* 
Characteristic No. (%) cases, n = 2,228†  Range per year, % (p value) 
Average reports per year, all cases  223 153–282  
Average annual incidence per 100,000 population  4.4 3.0–5.6  
Symptomatic cases  2,026 (91)  89–94 (0.44) 
Asymptomatic cases  202 (9)  6–11 (0.44) 
Secondary case‡  246 (12)‡  4–20 (<0.0005) 
Primary case‡  1,780 (888)‡  80–96 (<0.0005) 
Bloody diarrhea§  660 (59)§  56–62 (0.80) 
Hospitalized case-patients  902 (41)  29–48 (<0.0005) 
Hemolytic uremic syndrome  196 (9)  6–14 (0.03) 
Outbreak case  441 (20)  13–27 (<0.0005) 
Sporadic case  1,787 (80)  73–87 (<0.005) 
Sporadic and symptomatic¶  1,650 (92) ¶  90–95 (0.84) 
Sporadic, symptomatic, and secondary#  158 (10)#  3–15 (<0.005) 
Sporadic, symptomatic, and primary#  1,492 (90)#  85–97 (<0.005) 
*Cases include symptomatic and asymptomatic persons. 
†Unless otherwise indicated. 
‡Denominator = 2,026 symptomatic cases 1999–2008. 
§Denominator = 1,118 cases reported 2004–2008, all with symptom details available (1,022 symptomatic and 96 asymptomatic cases).
¶Denominator = 1,787 sporadic cases. 
#Denominator = 1,650 symptomatic sporadic cases. Inﬂ  uences affecting real incidence may include the relative 
population densities of livestock and humans and reliance 
on private water supplies (8).
Ascertainment of secondary cases in Scotland, which 
appeared to have a greater role in our study than may 
have been commonly assumed previously, may however 
be particularly affected by artifactual inﬂ  uences, such as 
more assiduous contact tracing resulting from heightened 
awareness, perhaps triggered by a combination of large 
outbreaks, a national task force, and enhanced surveillance 
(7,8). This possibility necessitates caution in extrapolating 
our ﬁ  ndings on secondary case incidence to other countries. 
Such tracing and conﬁ  rmation of infection is valuable in 
controlling household transmission as well as outbreaks, 
and for clinical management (10,11). Alternatively, 
some secondary cases will undoubtedly be missed, or 
misclassiﬁ  ed as primary cases.
Because most secondary cases in Scotland are 
apparently sporadic, our ﬁ  ndings also reinforce the need 
for low thresholds for suspecting infectious etiology in 
acute diarrhea (particularly if bloody), irrespective of 
(and without waiting to discover) whether cases are part 
of outbreaks (2,11). Patients need immediate advice about 
infection control in the home, accompanied by immediate 
stool sampling and monitoring (e.g., blood parameters), not 
just for primary or index cases but also for their contacts 
(9–11). We must continually raise professional and public 
awareness of secondary spread and measures needed to 
reduce it, and to ameliorate health outcomes (2,9,10). We 
should also maintain preventive strategies targeting the 
livestock-related risks strongly associated with sporadic 
infection (8,14,15).
We believe enhanced surveillance in Scotland 
provides uniquely valuable information, particularly about 
secondary transmission, because data derive from the 
entire population and standardized and long term. They 
remove reliance on extrapolating from studies of outbreaks, 
subgroups, or other countries, which may use substantially 
different methods and settings. Our data also permit robust 
long-term analysis, which is central to identifying whether 
differences in incidence or epidemiology are real or 
artifactual, and whether those differences are meaningful 
for public health.
We strongly recommend increased efforts to prevent 
secondary transmission within individual households. This 
would reduce not only the overall health and social costs of 
E. coli O157 infection but also the number of, and distress 
to, HUS cases attributable to secondary spread. 
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